First, simple memory tool for early recognition of rare types of lymphoma

Trinity researchers, along with UK collaborators, have created a simple but powerful diagnostic tool, which they believe will ...

Rare cancer study findings from Birmingham hospital hailed

Researchers at Queen Elizabeth Hospital Birmingham (QEHB), a leading centre for the PROCLIPI Study, have contributed to new ...

Dupixent and cancer risks: What patients need to know about lymphoma concerns

Dupixent (dupilumab) has been a breakthrough treatment for people with severe eczema, asthma, and other inflammatory ...
Health

What Happens to Your Skin When You Use a Heating Pad Too Often

Toasted skin syndrome causes a net-like rash to appear where the skin has been exposed to a heat source. It may resolve on ...
emjreviews.com

Editor’s Pick: Skin Intelligence: Advancing Cutaneous Resilience Through Biological Education, Microbial Symbiosis, and Eco-integrated Approaches

This review offers a forward-looking approach to dermatology, framing the skin as a dynamic and adaptive organ. By exploring barrier function, immune modulation, neuroimmune pathways, and microbial ...
Benzinga.com

Regeneron's Libtayo Gains FDA Approval To Reduce Recurrence Risk In Skin Cancer Patients

On Wednesday, the U.S. Food and Drug Administration (FDA) approved Regeneron Pharmaceuticals Inc.’s (NASDAQ:REGN) PD-1 inhibitor Libtayo (cemiplimab-rwlc) as an adjuvant treatment for adult patients ...
BioSpace

Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

PRINCETON, N.J., Oct. 7, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...